Surrozen Q1 Revenue Hits $5M, Exceeds Consensus
Reports Q1 revenue $5M, consensus $4M. The company said, "Surrozen remains focused on advancing a new generation of ophthalmology therapeutics that are built on a foundation of Wnt pathway biology. Surrozen's pipeline leverages its Wnt biology expertise and antibody technologies to develop therapeutics targeting ophthalmic diseases with significant unmet medical needs."
